Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	lung cancer
ICD-0-3	C34
Methods	qPCR, RIP, Western blot etc.
Sample	lung cancer tissues, cell line (6HBE, A549, H1770, H596, H1975, H1650 and H1299)
Expression Pattern	up-regulated
Function Description	The lncRNA MIR4435-2HG was highly expressed in lung cancer tissues and correlated with histological grades and lymph node metastasis. Phenotypic analysis indicated that MIR4435-2HG knockdown inhibited lung cancer cell proliferation and invasion in vitro and in vivo. Notably, MIR4435-2HG knockdown suppressed the EMT (epithelial-mesenchymal transition) process and cancer stem cell traits of lung cancer cells. Mechanistically, MIR4435-2HG knockdown decreased the transactivation of B-catenin. MIR4435-2HG interacted with B-catenin and thus prevented its degradation by the proteasome system. High expression of lncRNA MIR4435-2HG correlates with lung cancer progression MIR4435-2HG promotes lung cancer cells proliferation and invasion MIR4435-2HG knockdown suppresses the EMT process and cancer stem cell traits MIR4435-2HG knockdown inhibits the B-catenin signalling. Kaplan-Meier analysis of the 52 patients with lung cancer revealed that high MIR4435-2HG expression in lung cancer tissues was significantly correlated with a reduction in overall survival.
Pubmed ID	29872866
Year	2018
Title	The lncRNA MIR4435-2HG promotes lung cancer progression by activating ?-catenin signalling.

External Links